The present invention provides C1orf54 polypeptides and variants thereof with myokine activity as well as compositions and methods for treating, ameliorating or preventing muscle-related disorders.

An ameliorating agent or a prophylactic agent is used to treat or prevent a muscle weakness symptom in a disease or a syndrome associated with a metabolic disorder. The ameliorating agent or prophylactic agent contains a compound having a morphinan skeleton typified by the compound below or a pharmacologically acceptable acid addition salt thereof as an active ingredient.

##STR00001##

An ameliorating agent or a prophylactic agent is used to treat or prevent a muscle weakness symptom in a disease or a syndrome associated with a metabolic disorder. The ameliorating agent or prophylactic agent contains a compound having a morphinan skeleton typified by the compound below or a pharmacologically acceptable acid addition salt thereof as an active ingredient.

##STR00001##

Methods of treating cancer related conditions using anamorelin are described.

Salts and solid forms of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, or a stereoisomer thereof, are disclosed. Compositions comprising and methods of using the salts and solid forms are also disclosed.

Methods and compositions are provided for increasing muscle hypertrophy, e.g., through the administration of novel combinations of natural products that inhibit SIRT1.

The present invention relates to compositions and methods for altering body composition in a subject, wherein the alteration of body composition is an increase in muscle mass and a reduction of fat mass simultaneously. The present invention also relates to compositions and methods for reducing fat mass in a subject. The compositions and methods also increase muscle volume and lean body mass in the subject. The present invention also relates to compositions that comprise a GDF8 inhibitor and an Activin A inhibitor and the use of such compositions to treat diseases and disorders characterized by increased fat mass, and/or decreased muscle volume.

The present invention relates to compositions and methods for altering body composition in a subject, wherein the alteration of body composition is an increase in muscle mass and a reduction of fat mass simultaneously. The present invention also relates to compositions and methods for reducing fat mass in a subject. The compositions and methods also increase muscle volume and lean body mass in the subject. The present invention also relates to compositions that comprise a GDF8 inhibitor and an Activin A inhibitor and the use of such compositions to treat diseases and disorders characterized by increased fat mass, and/or decreased muscle volume.

The present invention provides a novel use of Morchella active substance. The Morchella active substance is for manufacturing a composition for ameliorating Sarcopenia. The preparation method of the Morchella active substance comprises the following steps: (a) culturing Morchella mycelium in a plate media between 15° C. and 30° C. for 1 to 2 weeks; (b) inoculating the Morchella mycelium cultured in step (a) to a flask and culturing the Morchella mycelium between 15° C. and 30° C. with a pH of 2 to 6 for 4 to 7 days; and (c) inoculating the Morchella mycelium cultured in step (b) to a fermentation tank and culturing the Morchella mycelium between 15° C. and 30° C. with a pH of 2 to 6 for 6 to 10 days, so as to obtain a Morchella mycelium fermentation broth containing the Morchella active substance.

The present invention provides a novel use of Morchella active substance. The Morchella active substance is for manufacturing a composition for ameliorating Sarcopenia. The preparation method of the Morchella active substance comprises the following steps: (a) culturing Morchella mycelium in a plate media between 15° C. and 30° C. for 1 to 2 weeks; (b) inoculating the Morchella mycelium cultured in step (a) to a flask and culturing the Morchella mycelium between 15° C. and 30° C. with a pH of 2 to 6 for 4 to 7 days; and (c) inoculating the Morchella mycelium cultured in step (b) to a fermentation tank and culturing the Morchella mycelium between 15° C. and 30° C. with a pH of 2 to 6 for 6 to 10 days, so as to obtain a Morchella mycelium fermentation broth containing the Morchella active substance.